3 recruiting, 3 unknown, 2 active not recruiting. 8 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Recruiting 3, Unknown 3, Active not recruiting 2 |
| Phase 1 | 3 | Recruiting 2, Active not recruiting 1 |
Follow Secondary Central Nervous System Lymphoma: new trials by email Literature Review of Secondary Central Nervous System Lymphoma trials Research Report on Secondary Central Nervous System Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas Pemetrexed, Zanubrutinib, Autologous Stem Cell Transplant (ASCT) - Primary Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma | Phase 2 | Recruiting | Baptist Health South Florida | 15 | 2024-04-25 | 2026-03-03 |
| A Study of GNC-038, a Tetra-specific Antibody, in Patients With Central Nervous System Lymphoma (PCNSL) and Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL) GNC-038 - Primary Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma | Phase 1 / Phase 2 | Active not recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 7 | 2023-02-10 | 2025-09-26 |
| Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma Acalabrutinib - Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Jonsson Comprehensive Cancer Center | 24 | 2023-01-23 | 2026-03-10 |
| Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma Tafasitamab, Lenalidomide - CNS Lymphoma, Primary Central Nervous System Lymphoma | Phase 1 / Phase 2 | Recruiting | James Rubenstein | 35 | 2022-06-08 | 2026-07-14 |
| R-MTX-zanbrutinib in Secondary CNS Lymphoma Zanubrutinib, high-dose methotrexate (HD-MTX), rituximab - Secondary Central Nervous System Lymphoma | Phase 2 | Unknown | Peking University | 45 | 2021-02-26 | 2022-05-31 |
| A Study of F520 in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Secondary Central Nervous System Lymphoma (SCNSL) F520 - Primary Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma | Phase 2 | Unknown | Shandong New Time Pharmaceutical Co., LTD | 43 | 2020-11-01 | 2020-10-22 |
| Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS) TEDD-R, TEDDI-R, Ibrutinib - Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 48 | 2019-06-27 | 2026-10-16 |
| A Study to Evaluate ICP-022 in Patients With R/R PCNSL and SCNSL ICP-022 - PCNSL, Secondary Central Nervous System Lymphoma | Phase 2 | Unknown | Beijing InnoCare Pharma Tech Co., Ltd. | 61 | 2019-06-18 | 2022-10-12 |
Recurrence (2) · Lymphoma, Large B-Cell, Diffuse (1) · Neoplasms (1)
Disease Attributes (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Hemic and Lymphatic Diseases (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Lymphatic Diseases (1) · Lymphoma (1) · Lymphoma, B-Cell (1) · Lymphoma, Non-Hodgkin (1) · Lymphoproliferative Disorders (1) · Neoplasms (1) · Neoplasms by Histologic Type (1)
Methotrexate (2) · zanubrutinib (2) · Cytarabine (1) · Lenalidomide (1) · Pemetrexed (1) · Rituximab (1) · acalabrutinib (1) · ibrutinib (1) · isavuconazole (1) · tafasitamab (1)
Baptist Health South Florida (1) · Beijing InnoCare Pharma Tech Co., Ltd. (1) · James Rubenstein (1) · Jonsson Comprehensive Cancer Center (1) · National Cancer Institute (NCI) (1) · Peking University (1) · Shandong New Time Pharmaceutical Co., LTD (1) · Sichuan Baili Pharmaceutical Co., Ltd. (1)
United States (4) · China (3)
Caspian Oliai, MD (1) · James Rubenstein, MD, PhD (1) · Rahul Lakhotia, M.D. (1) · Wenbin Li (1) · Yuliya Linhares, M.D. (1)